<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Rivaroxaban - Use in High Body Weight Patients</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>

<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white;font-family: helvetica; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">
    Rivaroxaban - Use in High Body Weight Patients
    </h3>
  </div>

  <div class="card">
    <ul class="nav nav-tabs" role="tablist">
      <li class="nav-item" role="presentation">
        <a class="nav-link active" id="summary_tab" role="tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab">
          Summary
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="Phase_3_studies_tab" role="tab" data-bs-toggle="tab" data-bs-target="#Phase3" href="#Phase3" role="tab">
          Phase III Studies
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="RWE_tab" role="tab" data-bs-toggle="tab" href="#RWE">
          Real World Evidence
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="additional_lit_tab" role="tab" data-bs-toggle="tab" href="#additional_lit">
          Additional Literature
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id = "references_tab" role="tab" data-bs-toggle="tab" href="#references">
          References
        </a>
      </li>
    </ul>
  </div>

  <div class="tab-content">
    <div id="summary" class="tab-pane show active" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Summary
        </h1>
        <ul class="bullet">
          <li>
            Based on BMI classification, a BMI of 18.5-&lt;25 kg/m<sup>2</sup> is normal weight, BMI of 25-29.99 kg/m<sup>2</sup> is overweight (pre-obesity), and obesity is a BMI &ge;30 kg/m<sup>2</sup> (obese class I: 30.0-34.9 kg/m<sup>2</sup>, obese class II/III: &ge;35.0 kg/m<sup>2</sup>) (source: according to the World Health Organization and the Centers for Disease Control classification of weight cited in the literature).<sup>1,2</sup>
          </li>
          <li>
            In adults, extremes in body weight (&le;50 kg and &gt;120 kg) had a small influence on rivaroxaban maximum plasma concentrations (C<sub>max</sub>) (less than 25%). This suggested that no dose adjustment of rivaroxaban is necessary for body weight.<sup>3</sup> PK models of rivaroxaban based on DVT patients showed that there was minimal influence of body weight on C<sub>max</sub>. While volume of distribution was influenced by body weight, the effects were moderate and within the observed interindividual variability.<sup>4</sup>
          </li>
          <li>
            Based on the PK profile and available evidence, a clinical practice guide and guidelines suggest that standard doses of NOACs are considered appropriate in patients with a BMI &le;40 kg/m<sup>2</sup> (or weight &le;120 kg; barring other clinically relevant factors).<sup>5,6,7</sup> Data are less robust in obese patients with a BMI &ge;40 kg/m<sup>2</sup>.<sup>2,5</sup> If NOACs are used in patients with a BMI &gt;40 kg/m<sup>2</sup> (or weight >20 kg) for the treatment or primary prevention of VTE, standard doses of rivaroxaban (regardless of high BMI and weight) is suggested by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Drug approval is restricted to elective hip and knee arthroplasty and (in some countries) extended VTE prevention following acute medical illness. The regular assessment of peak and trough NOAC levels is not suggested, due to the lack of sufficient data to influence treatment decisions.<sup>7</sup> See papers cited for complete recommendations.<sup>2,5-7</sup>
          </li>
          <li>
            In the rivaroxaban phase III RCTs, there were differences in kg and BMI cut-offs by weight category (kg: &lt;60, &ge;60-&lt;90, &ge;90; &le;70, 70-90, &gt;90; or &le;50, 50-100, &ge;100) and/or BMI (kg/m<sup>2</sup>: &le;25, 25-&le;35, &gt;35 or 18.5-&lt;25, 25-&lt;30, &ge;30).<sup>8,10,11,12,13,15,16,19,21,22,23</sup> The highest weight was reported in some studies as 190 kg, 220 kg and 227 kg in the RECORD, EINSTEIN DVT/PE, ROCKET-AF, respectively.<sup>8,12,16</sup> Clinical outcomes were consistent across prespecified subgroups classified by body weight and/or BMI (see the <a id="link" onclick="link2()">Phase III Studies</a> 
            and <a id="link" onclick="link3()">Real World Evidence</a> tabs for more details).<sup>8-23</sup> Consistently, obesity (i.e. BMI &ge; 30 kg/m<sup>2</sup>) did not affect the safety/efficacy of rivaroxaban.<sup>2,8-10,12-23</sup> However, some studies noted that as a small proportion of the study population had class &ge;2 obesity, data should be interpreted with caution.<sup>2,12,21</sup> Large RCTs that specifically investigated the efficacy and safety of rivaroxaban in obese patients have not been conducted.
          </li>
          <li>
            Subsequent observational studies with comparative data from clinical trials in high body weight patients indicate no significant effect of body weight (including extreme weights &gt;120 kg) on the effectiveness and safety of rivaroxaban.<sup>24-27</sup> Additional real-world data cited in AF or VTE patients with varying degrees of obesity suggested that NOACs (including rivaroxaban) showed consistent efficacy and similar/lower major bleeding risks vs the comparator. Most papers summarized<sup>24-27</sup> and cited in the <a id="link" onclick="link4()">Additional Literature</a>, suggest that larger RCTs are needed to confirm the effect of NOACs in obese and/or morbidly obese patients.
          </li>
          <li>
            A literature search including PubMed, EMBASE and internal/external databases (on April 10th, 2023; articles in English published after 2018), retrieved the information contained within this letter on the use of rivaroxaban in high body weight patients.
          </li>
        </ul>
      </div><br>
    </div>

    <div id="Phase3" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Phase III Studies
        </h1>
        <div class="accordion">
          <div class="accordion-item">
            <h2 class="accordion-header" id="heading 1">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-1">
                RECORD</button>
            </h2>
            <div id="collapse-1" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  The pooled analysis of RECORD studies (6183 on rivaroxaban, 6200 on enoxaparin) in patients undergoing total hip/knee replacement procedures for VTE prevention, reported a consistent reduction in the composite of symptomatic VTE and all-cause mortality with rivaroxaban vs enoxaparin groups in those weighing &gt;90 kg (0.6% vs 1.3%; HR 0.49; 95% CI 0.22-1.09). Major plus CRNM bleeding occurred in 4.4% vs 2.7% of patients on rivaroxaban vs enoxaparin, respectively (HR 1.62; 95% CI 1.09–2.40).<sup>8,9</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="patients">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-2">
                EINSTEIN
              </button>
            </h2>
            <div id="collapse-2" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  In the acute VTE population in EINSTEIN DVT/PE (N=8282; 16.8% were &gt;100 kg), there was no association between body weight and risk of recurrent VTE (<em>P<sub>trend</sub></em>=0.87) or major bleeding (<em>P<sub>trend</sub></em>=0.24) in the rivaroxaban group. Major bleeding was numerically lower across all body weight categories with similar risks of recurrent VTE during the rivaroxaban treatment period. Though the sample of patients with a body weight &ge;140 kg (n=81) was relatively small, authors noted that caution should be applied when confronted with such extremely overweight patients.<sup>12</sup> In the continued VTE treatment population in EINSTEIN-Extension (N=1197; 14.1% rivaroxaban-treated patients were &gt;100 kg), of patients &gt;90 kg, recurrent VTE and major plus CRNM bleeding events occurred in 0.5% (1/187) and 7.6% (14/185) of patients in the rivaroxaban group, and 18/177 (10.2%) and 1/176 (0.6%) of patients in the placebo group, respectively.<sup>10,11</sup> In EINSTEIN CHOICE (N=3365), symptomatic recurrent VTE was seen in 1.8% (7/396), 1.3% (5/390), and 4.9% (18/367) ≥90 kg patients in the rivaroxaban 20 mg, rivaroxaban 10 mg and aspirin groups, respectively. Major and CRNM bleeding occurred in 3.1% (11/360), 2.5% (9/364) and 1.7% (6/346) of patients in the rivaroxaban 20 mg, rivaroxaban 10 mg and aspirin groups, respectively.<sup>13,14</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="results">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-3">
                ROCKET-AF
              </button>
            </h2>
            <div id="collapse-3" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  In a ROCKET AF post-hoc analysis in patients with non-valvular atrial fibrillation (NVAF; N=14&nbsp030; 39% had BMI of 25.0–29.9 kg/m<sup>2</sup> and 37% had BMI &ge;30 kg/m<sup>2</sup>), rates of SSE were significantly lower for overweight and obese patients compared with normal weight patients in both rivaroxaban and warfarin treatment groups (rivaroxaban: HR 0.62, 95% CI 0.40-0.96, <em>P</em>=0.033; warfarin: HR 0.48, 95% CI 0.31-0.74, <em>P</em>&lt;0.001). For rivaroxaban, rates of major or CRNM bleeding were significantly different among BMI groups and highest among overweight patients (<em>P<sub>trend</sub></em>=0.01).<sup>18</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="efficacy outcomes">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-4">
                ATLAS ACS 2-TIMI 51
              </button>
            </h2>
            <div id="collapse-4" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  Body weight did not have a clinically relevant effect on treatment efficacy or major bleeding (not related to CABG) when rivaroxaban (2.5 mg BID or 5 mg BID) was used as adjunctive therapy in patients with recent ACS in ATLAS ACS 2-TIMI 51. In patients weighted &ge;90 kg, a MACE was reported in 150/2494 (6.0%) of patients in the rivaroxaban group vs 89/1215 (7.3%) in the placebo group (HR 0.83; 95% CI 0.64-1.08). TIMI major bleeding (not related to CABG) occurred in 33/2473 (1.3%) rivaroxaban vs 3/1204 (0.2%) placebo-treated patients (HR 5.46; 95% CI 1.67-17.81).<sup>19,20</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="safety outcomes">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-5">
                COMPASS
              </button>
            </h2>
            <div id="collapse-5" class="accordion-collapse collapse" >
              <div class="accordion-body">
                <p class="collapse-text">
                  A secondary analysis of 27&nbsp376 COMPASS patients with coronary artery disease and/or PAD (44% were overweight; 32% were obese, and 528 with extreme Class III obesity), found that MACE was borderline increased in those with BMI &ge;30 kg/m<sup>2</sup> compared with a BMI of 25-&lt;30 kg/m<sup>2</sup>. Major bleeding risk incidence was 3.2% on the vascular dose of rivaroxaban of 2.5 mg BID plus aspirin and 2.1% on aspirin alone with shrinkage HR of 1.59 (95% CI 1.21-2.06). While very high body weight (&gt;120 kg; n=318) did not show significant treatment–body weight interaction for MACE or major bleeding, the authors noted that the observations related to subjects with extreme weight &gt;120 kg need to be interpreted with caution, as the number of patients in this subgroup was small. Authors concluded that a dose adjustment is not necessary in overweight and obese patients for the dual-pathway anticoagulant regimen in these subjects.<sup>21</sup>
                </p>
              </div>
            </div>
          </div>  
          
          <div class="accordion-item">
            <h2 class="accordion-header" id="efficacy outcomes">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-6">
                VOYAGER PAD
              </button>
            </h2>
            <div id="collapse-6" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  In VOYAGER PAD patients (N=6564) who had undergone lower-extremity revascularization, the effects of the vascular dose of rivaroxaban plus aspirin vs aspirin alone on atherothrombotic vascular outcomes were consistent among BMI subgroups. The vascular dose of rivaroxaban plus aspirin reduced the incidence of major adverse limb and CV events vs aspirin use alone in those weighing &ge;26 kg/m<sup>2</sup> (HR 0.85; 95% CI 0.72-1.01). The incidence of TIMI-major bleeding was not significantly higher with the vascular dose of rivaroxaban plus aspirin than with aspirin alone (HR 1.16; 95% CI 0.62-2.17).<sup>22,23</sup>
                </p>
              </div>
            </div>
          </div>
        </div><br>
      </div><br>
    </div>
            
    <div id="RWE" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Real World Evidence
        </h1>
        <p>
          The outcomes of observational studies investigating the effectiveness and safety of NOACs in ≥10&nbsp000 high body weight AF patients are consistent with the growing body of evidence on rivaroxaban use in patients with obesity. It must be emphasized that due to the differences in patient populations and study methods, there are limitations of directly comparing results from the real-world evidence with above post-hoc analyses of RCTs.
          <br><br>
          The retrospective cohort study by <b>Weir et al (2021)</b> compared the risk of SSE and major bleeding in NVAF patients with obesity and diabetes who were initiated on rivaroxaban (n=12&nbsp663) or warfarin therapy (n=18&nbsp415). In the rivaroxaban group, 40.3% were identified as class I obese, 15.3% as class II and 44.4% as class III. In the intent-to-treat subgroup analysis by obesity class, the risk of SSE was lower with rivaroxaban vs warfarin in all 3 obesity classes, with significant reductions in class I (HR 0.80; 95% CI 0.69-0.92) and class III (HR 0.82; 95% CI 0.70-0.95) but not class II (HR 0.80; 95% CI 0.62-1.04). No statistical differences were observed in major bleeding risk between cohorts in each of the 3 obesity classes.<sup>24</sup>
          <br><br>
          In an observational study of administrative United States (U.S.) data in a cohort of younger NVAF patients with obesity (10&nbsp555 on rivaroxaban, 5080 on warfarin) <b>(Berger et al., 2021)</b>, rivaroxaban was associated with a 26% lower risk of SSE compared with warfarin (HR 0.74; 95% CI 0.60-0.91, <em>P</em>=0.004), with a similar risk of major bleeding up to 36 months (HR 0.85; 95% CI 0.71-1.02, <em>P</em>=0.085).<sup>25</sup> In another large real-world study of administrative data in NVAF obese patients <b>(Costa et al., 2020)</b> (35&nbsp613 on rivaroxaban and 35&nbsp613 on warfarin; 48% of patients had a BMI of 30.0-34.9-kg/m<sup>2</sup>, 27% a BMI of 35.0-39.9 kg/m<sup>2</sup> and 25% a BMI &ge;40 kg/m<sup>2</sup>; ~28% had a body weight &gt;120 kg), rivaroxaban was associated with a significant 17% reduction in the hazard of SSE (HR 0.83; 95% CI 0.73-0.94) and 18% reduction in major bleeding (HR 0.82; 95% CI 0.75-0.89) compared to warfarin in patients with a BMI &ge;30 kg/m<sup>2</sup>. There was no significant difference across BMI classes for SSE (<em>P<sub>interaction</sub></em>=0.58) or major bleeding (<em>P<sub>interaction</sub></em>=0.44) outcomes.<sup>26</sup>
          <br><br>
          A retrospective cohort analysis <b>(Costa et al., 2021)</b> of 13&nbsp510 (after 1:1 propensity-score matching) obese acute VTE patients (47% of patients had a BMI of 30.0-34.9, 26% a BMI of 35.0-39.9 and 26% a BMI &ge;40) reported that rivaroxaban-treated patients had a significantly reduced risk of recurrent VTE at 3-, 6-, and 12-months (3.12% vs 5.17%, HR 0.61, 95% CI 0.51-0.72; 3.38% vs 5.23%; HR 0.65, 95% CI 0.55-0.77; 3.72% vs 5.25%, HR 0.63, 95% CI 0.54-0.74, respectively) and no increased risk of major bleeding (0.80% vs 0.83%, HR 0.99, 95% CI 0.68-1.44; 0.93% vs 1.08%, HR 0.90, 95% CI 0.64-1.26; 1.15% vs 0.92%, HR 1.00, 95% CI 0.73-1.36, respectively) compared with warfarin-treated patients. Effects were consistent across BMI categories. Due to the use of U.S.-based data, authors noted that study findings are most generalizable to the U.S. population.<sup>27</sup>
          <br>
        </p>
      </div><br>
    </div>
        
    <div id="additional_lit" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Additional Literature
        </h1>
        <p>
          Additional RWE in this clinical setting, published after 2016 (in English), (with &le;2000 patients) have also been cited below for your perusal:
        </p>
        <div class="accordion">
          <div class="accordion-item">
            <h2 class="accordion-header">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-6">
                RWE Specific to Rivaroxaban
              </button>
            </h2>
            <div id="collapse-6" class="accordion-collapse collapse">
              <div class="accordion-body">
                <ul class="bullet-collapse">
                  <li>
                    Weaver P, Ng TH, Breeden T, et al. Management of Venous Thromboembolism in Morbid Obesity with Rivaroxaban or Warfarin. <em>Ann Pharmacother</em>. 2022;56(12):1315-1324. 
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/35505606/" target="_blank">PMID: 35505606</a>
                  </li>
                  <li>
                    Berger J, Laliberte F, Kharat A, et al. Comparative effectiveness and safety of rivaroxaban and warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity and polypharmacy in the United States (US). <em>Adv Ther</em>. 2021;38(7):3771-3788.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/34031859/" target="_blank">PMID: 34031859</a>
                  </li>
                  <li>
                    Costa OS, Beyer-Westendorf J, Ashton V, et al. Rivaroxaban Versus Warfarin for Management of Obese African Americans with Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. <em>Clin Appl Thromb Hemost</em>. 2020;26:1076029620954910.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/33085526/" target="_blank">PMID: 33085526</a>
                  </li>
                  <li>
                    Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. <em>Ann Pharmacother</em>. 2020;54(4):344-350.
                   <br><a href="https://pubmed.ncbi.nlm.nih.gov/31672028/" target="_blank">PMID: 31672028</a>
                  </li>
                  <li>
                    Wysokinski WE, Froehling DA, Houghton DE, et al. Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. <em>Eur J Haematol</em>. 2020;105(4):484-494. 
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/32557773/" target="_blank">PMID: 32557773</a>
                  </li>
                  <li>
                    Murakawa Y, Ikeda T, Ogawa S, et al. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation. <em>Heart Vessels</em>. 2020;35(8):1125-1134. 
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/32253531/" target="_blank">PMID: 32253531</a>
                  </li>
                  <li>
                    Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. <em>Thromb Res</em>. 2019;182:159-166. 
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/31493618/" target="_blank">PMID: 31493618</a>
                  </li>
                  <li>
                    Krauss ES, Cronin MA, Dengler N, et al. The Effect of BMI and Gender on Bleeding Events when Rivaroxaban Is Administered for Thromboprophylaxis Following Total Hip and Total Knee Arthroplasty. <em>Semin Thromb Hemost</em>. 2019;45(2):180-186.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/30566970/" target="_blank">PMID:  30566970</a>
                  </li>
                  <li>
                    Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. <em>Am Heart J</em>. 2019;212:113-119.
                  <br><a href="https://pubmed.ncbi.nlm.nih.gov/30981035/" target="_blank">PMID: 30981035</a></li>
                </ul>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-7">
                RWE Specific to NOACs, Including Rivaroxaban
              </button>
            </h2>
            <div id="collapse-7" class="accordion-collapse collapse">
              <div class="accordion-body">
                <ul class="bullet-collapse">
                  <li>
                    Caverley ZR, Blindler RJ, Soh P, Mendelson S. Direct oral anticoagulants and warfarin safety in rural patients with obesity. <em>Am J Med Sci</em>. 2023;365(5):413-419.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/36693495/" target="_blank">PMID: 36693495</a>
                  </li>
                  <li>
                    Chugh Y, Gupta K, Krishna HB, et al. Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis. Pacing Clin Electrophysiol. 2023;46(1);50-58.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/36419246/" target="_blank">PMID: 36419246</a>
                  </li>
                  <li>
                    Bodega F, Russi A, Melillo F, et al; INSigHT investigators. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight. <em>Eur J Clin Invest</em>. 2022;52(1):e13658.
                   <br><a href="https://pubmed.ncbi.nlm.nih.gov/34310688/" target="_blank">PMID: 34310688</a>
                  </li>
                  <li>
                    O'Kane CP, Avalon JCO, Lacoste JL, et al. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m<sup>2</sup>. <em>Pharmacotherapy</em>. 2022;42(2):112-118.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/34820876/" target="_blank">PMID: 34820876</a>
                  </li>
                  <li>
                    Nakao YM, Nakao K, Wu J, Nadarajah R, Camm AJ, Gale CP. Risks and benefits of oral anticoagulants for stroke prophylaxis in atrial fibrillation according to body mass index: Nationwide cohort study of primary care records in England. <em>E Clinical Medicine</em>. 2022;54:101709.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/36353266/" target="_blank">PMID: 36353266</a>
                  </li>
                  <li>
                    Aloi KG, Fierro JJ, Stein BJ, Lynch SM, Shapiro RJ. Investigation of Direct-Acting Oral Anticoagulants and the Incidence of Venous Thromboembolism in Patients Weighing ≥120 kg Compared to Patients Weighing <120 kg. <em>J Pharm Pract</em>. 2021;34(1):64-69.
                   <br><a href="https://pubmed.ncbi.nlm.nih.gov/31238775/" target="_blank">PMID: 31238775</a>
                  </li>
                  <li>
                    Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, Sarrazin MSV. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. <em>Cardiovasc Drugs Ther</em>. 2021;35(2):261-272.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/33404923/" target="_blank">PMID: 33404923</a>
                  </li>
                  <li>
                    Wiethorn EE, Bell CM, Wiggins BS. Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥120 Kilograms versus 60-120 Kilograms. <em>Am J Cardiovasc Drugs</em>. 2021;21(5):545-551.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/33782909/" target="_blank">PMID: 33782909</a>
                  </li>
                  <li>
                    Russo V, Bottino R, Rago A, et al. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. Semin Thromb Hemost. 2020;46(8):970-976. <em>Semin Thromb Hemost</em>. 2020;46(18):970-976.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/33105504/" target="_blank">PMID: 33105504</a>
                  </li>
                  <li>
                    Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. <em>Pharmacotherapy</em>. 2020;40(3):204-210.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/31968126/" target="_blank">PMID: 31968126</a>
                  </li>
                  <li>
                    Kalani C, Awudi E, Alexander T, Udeani G, Surani S. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. <em>Hosp Pract (1995)</em>. 2019;47(4):181-185.
                   <br><a href="https://pubmed.ncbi.nlm.nih.gov/31580732/" target="_blank">PMID: 31580732</a>
                  </li>
                  <li>
                    Kido K and Ngorsuraches S. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. <em>Ann Pharmacother</em>. 2019;53(2):165-170.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/30130979/" target="_blank">PMID: 30130979</a>
                  <li>
                    Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-center, retrospective analysis of chart data. <em>Lancet Haematol</em>. 2019;6(7):e359-e365.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/31133411/" target="_blank">PMID: 31133411</a>
                  </li>
                  </li>
                  <li>
                    Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC registry (NCT01588119). <em>Int J Cardiol</em>. 2018;262:85-91.
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/29622509/" target="_blank">PMID: 29622509</a>
                  </li>
                </ul>
              </div>
            </div>
          </div>
        </div><br>
      </div><br>
    </div>

    <div id="references" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          References
        </h1>
          <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px;padding-bottom: 10px; padding-top: 10px;font-size: 20px;background-color: #f7f7f7;">
            <li>
              Uprichard J. Management of rivaroxaban in relation to bodyweight and body mass index. <em>Ther Adv Cardiovasc</em>. 2016;10(5):294-303.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/27090286/' target='_blank'>PMID: 27090286</a>
            </li>
            <li>
              Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <em>Eur Heart J</em>. 2018;39(19):1672-1686f. 
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/29509886/' target='_blank'>PMID: 29509886</a>
            </li>
            <li>
              Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. <em>J Clin Pharmacol</em>. 2007;47(2);218-226.            <br><a href='https://pubmed.ncbi.nlm.nih.gov/17244773/' target='_blank'>PMID: 17244773</a>
            </li>
            <li>
              Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. <em>Clin Pharmacokinet</em>. 2011;50(10):675-686.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/21895039/' target='_blank'>PMID: 21895039</a>
            </li>
            <li>
              Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation [published correction appears in <em>Europace</em>. 2021 Oct 9]. <em>Europace</em>. 2021;23(10):1612-1676.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/33895845/' target='_blank'>PMID: 33895845</a>
            </li>
            <li>
              Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2016;14(6):1308-1313.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/27299806/' target='_blank'>PMID: 27299806</a>
            </li>
            <li>
              Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <em>J Thromb Haemost</em>. 2021;19(8):1874-1882.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/34259389/' target='_blank'>PMID: 34259389</a>
            </li>
            <li>
              Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. <em>Thromb Haemost</em>. 2011;105(3):444-53.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/21136019/' target='_blank'>PMID: 21136019</a>
            </li>
            <li>
              <a href='https://www.thieme-connect.de/media/10.1055-s-00035024/201103/supmat/10-1160-th10-09-0601-supp.pdf' target='_blank'>Supplement to</a>: Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. <em>Thromb Haemost</em>. 2011;105(3):444-53.
            </li>
            <li>
              EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <em>N Engl J Med</em>. 2010;363(26):2499-2510.            
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/21128814/' target='_blank'>PMID: 21128814</a>
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_appendix.pdf' target='_blank'>Supplement for</a>: EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <em>N Engl J Med</em>. 2010;363(26):2499-2510.
            <li>
              Di Nisio M, Vedovati MC, Riera-Mestre A, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. <em>Thromb Haemost</em>. 2016;116(4):739-46.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/27535349/' target='_blank'>PMID: 27535349</a>
            </li>
            <li>
              Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <em>N Engl J Med</em>. 2017;376(13):1211-1222.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/28316279/' target='_blank'>PMID: 28316279</a>
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1700518/suppl_file/nejmoa1700518_appendix.pdf' target='_blank'>Supplement to</a>: Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <em>N Engl J Med</em>. 2017;376(13):1211-1222.
            </li>
            <li>
              Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <em>N Engl J Med</em>. 2011;365(10):883-91.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/21830957/' target='_blank'>PMID: 21830957</a>
            </li>
            <li>
              FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC), Meeting on September 8, 2011, for the indication - Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Available at: <a href='https://wayback.archive-it.org/7993/20170405211959/https:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf' target='_blank'>Link</a> <br>Accessed April 14th, 2023. (Available in the public domain)
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_appendix.pdf' target='_blank'>Supplement to</a>: Patel MR, Mahaffey KW, Garg J, et al for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <em>N Engl J Med</em>. 2011;365(10):883-91.
            </li>
            <li>
              Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). <em>Am J Cardiol</em>. 2017;119(12):1989-1996.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/28477860/' target='_blank'>PMID: 28477860</a>
            </li>
            <li>
              Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <em>N Engl J Med</em>. 2012;366(1):9-19.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/22077192/' target='_blank'>PMID: 22077192</a>
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1112277/suppl_file/nejmoa1112277_appendix.pdf' target='_blank'>Supplement to</a>: Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <em>N Engl J Med</em>. 2012;366(1):9-19.
            </li>
            <li>
              Guzik TJ, Ramasundarahettige C, Pogosova N, et al. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <em>J Am Coll Cardiol</em>. 2021;77(5):511-525.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/33538248/' target='_blank'>PMID: 33538248</a>
            </li>
            <li>
              Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. <em>N Engl J Med</em>. 2020;382(21):1994-2004.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/32222135/' target='_blank'>PMID: 32222135</a>
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa2000052/suppl_file/nejmoa2000052_appendix.pdf' target='_blank'>Supplement to</a>: Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. <em>N Engl J Med</em>. 2020;382(21):1994-2004.
            </li>
            <li>
              Weir MR, Chen YW, He J, Bookhart B, Campbell A, Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. <em>J Diabetes Complications</em>. 2021;35(11):108029.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/34538715/' target='_blank'>PMID: 34538715</a>
            </li>
            <li>
              Berger JS, Laliberté F, Kharat A, et al. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. <em>Curr Med Res Opin</em>. 2021;37(6):881-890.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/33733969/' target='_blank'>PMID: 33733969</a>
            </li>
            <li>
              Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <em>Curr Med Res Opin</em>. 2020;36(7):1081-1088.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/32347755/' target='_blank'>PMID: 32347755</a>
            </li>
            <li>
              Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <em>J Thromb Thrombolysis</em>. 2021;51(2):349-358.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/32588288/' target='_blank'>PMID: 32588288</a>
            </li>
          </ol>">
      </div>
    </div><br><br>
  </div>   

  <footer class="fixed-bottom">
    <div class="container-fluid">
      <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="Abbreviations" onclick="changeIcon(this)" data-bs-content="
        <strong>ACS</strong> acute coronary syndrome<br>
        <strong>AF</strong> atrial fibrillation<br>
        <strong>BID</strong> twice daily<br>
        <strong>BMI</strong> body mass index<br>
        <strong>CABG</strong> coronary artery bypass grafting<br> 
        <strong>CAD</strong> coronary artery disease<br> 
        <strong>CI</strong> confidence interval<br>
        <strong>CRNM</strong> clinically relevant nonmajor<br>
        <strong>DVT</strong> deep vein thrombosis<br>
        <strong>HR</strong> hazard ratio<br>
        <strong>MACE</strong> major adverse cardiovascular event<br>
        <strong>MI</strong> myocardial infarction<br>
        <strong>NOAC</strong> non-vitamin K antagonist oral anticoagulants<br>
        <strong>NVAF</strong> non-valvular atrial fibrillation<br>
        <strong>PAD</strong> peripheral arterial disease<br>
        <strong>PE</strong> pulmonary embolism<br>
        <strong>PK</strong> pharmacokinetic<br>
        <strong>RCT</strong> randomized controlled trial<br>
        <strong>RWE</strong> real world evidence<br>
        <strong>SSE</strong> stroke and systemic embolism<br>
        <strong>TIMI</strong> Thrombolysis in Myocardial Infarction<br>
        <strong>Vka</strong> vitamin K antagonist<br>
        <strong>VTE</strong> venous thromboembolism<br>">
        <i id ="fa" class="fas fa-list"></i>
      </button>
  
      <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="References" onclick="changeIcon(this)" data-bs-content="
        <ol>
          <li>
            Uprichard J. Management of rivaroxaban in relation to bodyweight and body mass index. <em>Ther Adv Cardiovasc</em>. 2016;10(5):294-303.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/27090286/' target='_blank'>PMID: 27090286</a>
          </li>
          <li>
            Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <em>Eur Heart J</em>. 2018;39(19):1672-1686f. 
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/29509886/' target='_blank'>PMID: 29509886</a>
          </li>
          <li>
            Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. <em>J Clin Pharmacol</em>. 2007;47(2);218-226.            <br><a href='https://pubmed.ncbi.nlm.nih.gov/17244773/' target='_blank'>PMID: 17244773</a>
          </li>
          <li>
            Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. <em>Clin Pharmacokinet</em>. 2011;50(10):675-686.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/21895039/' target='_blank'>PMID: 21895039</a>
          </li>
          <li>
            Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation [published correction appears in <em>Europace</em>. 2021 Oct 9]. <em>Europace</em>. 2021;23(10):1612-1676.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/33895845/' target='_blank'>PMID: 33895845</a>
          </li>
          <li>
            Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2016;14(6):1308-1313.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/27299806/' target='_blank'>PMID: 27299806</a>
          </li>
          <li>
            Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <em>J Thromb Haemost</em>. 2021;19(8):1874-1882.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/34259389/' target='_blank'>PMID: 34259389</a>
          </li>
          <li>
            Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. <em>Thromb Haemost</em>. 2011;105(3):444-53.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/21136019/' target='_blank'>PMID: 21136019</a>
          </li>
          <li>
            <a href='https://www.thieme-connect.de/media/10.1055-s-00035024/201103/supmat/10-1160-th10-09-0601-supp.pdf' target='_blank'>Supplement to</a>: Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. <em>Thromb Haemost</em>. 2011;105(3):444-53.
          </li>
          <li>
            EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <em>N Engl J Med</em>. 2010;363(26):2499-2510.            
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/21128814/' target='_blank'>PMID: 21128814</a>
          </li>
          <li>
            <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_appendix.pdf' target='_blank'>Supplement for</a>: EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <em>N Engl J Med</em>. 2010;363(26):2499-2510.
          <li>
            Di Nisio M, Vedovati MC, Riera-Mestre A, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. <em>Thromb Haemost</em>. 2016;116(4):739-46.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/27535349/' target='_blank'>PMID: 27535349</a>
          </li>
          <li>
            Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <em>N Engl J Med</em>. 2017;376(13):1211-1222.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/28316279/' target='_blank'>PMID: 28316279</a>
          </li>
          <li>
            <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1700518/suppl_file/nejmoa1700518_appendix.pdf' target='_blank'>Supplement to</a>: Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <em>N Engl J Med</em>. 2017;376(13):1211-1222.
          </li>
          <li>
            Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <em>N Engl J Med</em>. 2011;365(10):883-91.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/21830957/' target='_blank'>PMID: 21830957</a>
          </li>
          <li>
            FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC), Meeting on September 8, 2011, for the indication - Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Available at: <a href='https://wayback.archive-it.org/7993/20170405211959/https:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf' target='_blank'>Link</a> <br>Accessed April 14th, 2023. (Available in the public domain)
          </li>
          <li>
            <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_appendix.pdf' target='_blank'>Supplement to</a>: Patel MR, Mahaffey KW, Garg J, et al for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <em>N Engl J Med</em>. 2011;365(10):883-91.
          </li>
          <li>
            Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). <em>Am J Cardiol</em>. 2017;119(12):1989-1996.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/28477860/' target='_blank'>PMID: 28477860</a>
          </li>
          <li>
            Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <em>N Engl J Med</em>. 2012;366(1):9-19.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/22077192/' target='_blank'>PMID: 22077192</a>
          </li>
          <li>
            <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa1112277/suppl_file/nejmoa1112277_appendix.pdf' target='_blank'>Supplement to</a>: Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. <em>N Engl J Med</em>. 2012;366(1):9-19.
          </li>
          <li>
            Guzik TJ, Ramasundarahettige C, Pogosova N, et al. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <em>J Am Coll Cardiol</em>. 2021;77(5):511-525.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/33538248/' target='_blank'>PMID: 33538248</a>
          </li>
          <li>
            Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. <em>N Engl J Med</em>. 2020;382(21):1994-2004.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/32222135/' target='_blank'>PMID: 32222135</a>
          </li>
          <li>
            <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa2000052/suppl_file/nejmoa2000052_appendix.pdf' target='_blank'>Supplement to</a>: Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. <em>N Engl J Med</em>. 2020;382(21):1994-2004.
          </li>
          <li>
            Weir MR, Chen YW, He J, Bookhart B, Campbell A, Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. <em>J Diabetes Complications</em>. 2021;35(11):108029.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/34538715/' target='_blank'>PMID: 34538715</a>
          </li>
          <li>
            Berger JS, Laliberté F, Kharat A, et al. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. <em>Curr Med Res Opin</em>. 2021;37(6):881-890.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/33733969/' target='_blank'>PMID: 33733969</a>
          </li>
          <li>
            Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <em>Curr Med Res Opin</em>. 2020;36(7):1081-1088.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/32347755/' target='_blank'>PMID: 32347755</a>
          </li>
          <li>
            Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <em>J Thromb Thrombolysis</em>. 2021;51(2):349-358.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/32588288/' target='_blank'>PMID: 32588288</a>
          </li>
        </ol>">
        <i id="fa" class="fas fa-scroll"></i>
      </button>
    </div>
    <a href="#" id="scroll" style="display: none;"><span></span></a>
  </footer>

  <script>  
    var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
    var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
    {
        return new bootstrap.Popover(popoverTriggerEl)
      });
  </script>
  
</body>
</html>